7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin sulfuric acid salt

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin sulfuric acid salt
• 英文别名: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;sulfuric acid
• 化学式: C₃₃H₃₈N₄O₆*H₂O₄S
• 分子量: 684.767
• InChiKey: RAKWNZPJOZIRCE-WAQYZQTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.44
• 重原子数：
  48
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  196
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  伊立替康 在 硫酸 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 20.0h， 生成 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carboxyoxycamptothecin sulfuric acid salt
  参考文献：
  名称：

  EP1798235

  摘要：

  公开号：

文献信息

• ACID ADDITION SALT OF IRINOTECAN
  申请人：KABUSHIKI KAISHA YAKULT HONSHA

  公开号：EP1798235A1

  公开（公告）日：2007-06-20

  The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, citric acid, maleic acid, and succinic acid to irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.

  本发明涉及一种伊立替康酸加成盐，它是通过将选自硫酸、硝酸、磷酸、甲磺酸、柠檬酸、马来酸和琥珀酸组成的组中的一种酸加成到伊立替康中而形成的，本发明还涉及一种生产该盐的方法，以及一种含有该盐的药物组合物。这种添加盐在药物制备过程中不需要加热过程，并能提供一种盐能稳定溶解的水性药物产品。
• EP1798235B1
  申请人：——

  公开号：EP1798235B1

  公开（公告）日：2015-04-01
• BLOOD-COAGULATION INHIBITING MATERIAL, COATING MATERIAL AND IN VIVO INDWELLING MEMBERS MADE BY USING THE MATERIAL, AND METHOD OF TREATMENT
  申请人：National Cerebral and Cardiovascular Center

  公开号：EP2098256B1

  公开（公告）日：2016-06-08
• Acid Addition Salt of Irinotecan
  申请人：Shimizu Hideaki

  公开号：US20070299099A1

  公开（公告）日：2007-12-27

  The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.
• BLOOD ANTICOAGULANT MATERIAL, COATING MATERIAL AND INDWELLING DEVICE COMPRISING THE SAME, AND TREATMENT USING BLOOD ANTICOAGULANT MATERIAL
  申请人：Yamaoka Tetsuji

  公开号：US20100030325A1

  公开（公告）日：2010-02-04

  A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R 1 , R 2 , and R 3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.